Filed Pursuant to Rule 424(b)(3)
Registration No. 333-229498
PROSPECTUS SUPPLEMENT NO. 10
(to Prospectus dated March 8, 2019)
REPRO MED SYSTEMS, INC.
11,101,697 shares of common stock
This prospectus supplement No. 10 supplements and amends the prospectus dated March 8, 2019, as supplemented by prospectus supplement No. 1, dated April 29, 2019, as further supplemented by prospectus supplement No. 2, dated May 7, 2019, prospectus supplement No. 3, dated May 8, 2019, prospectus supplement No. 4, dated June 27, 2019, prospectus supplement No. 5, dated July 2, 2019, prospectus supplement No. 6, dated August 7, 2019, prospectus supplement No. 7, dated September 4, 2019, prospectus supplement No. 8, dated October 1, 2019 and prospectus supplement No. 9, dated October 14, 2019 (collectively, the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-229498). This prospectus supplement is being filed to update and supplement the information in the Prospectus with information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on October 23, 2019 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.
The Prospectus and this prospectus supplement relate solely to 11,101,697 shares of Repro Med Systems, Inc. common stock, par value $0.01 per share, which we refer to as our common stock, which may be offered for sale from time to time by the stockholders named under the heading “Selling Stockholders” in the Prospectus.
This prospectus supplement should be read in conjunction with the Prospectus, including any supplements or amendments thereto. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.
Our common stock is currently listed on the NASDAQ Capital Market under the symbol “REPR.” The closing price of our common stock as reported on the NASDAQ Capital Market on October 21, 2019, was $4.08.
Investing in our common stock involves risks, and you should not invest unless you can afford to lose your entire investment. See the section entitled “Risk Factors” beginning on page 5 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is October 23, 2019.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 23, 2019
REPRO MED SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
New York | 0-12305 | 13-3044880 |
(State or other jurisdiction | (Commission | (IRS Employer |
24 Carpenter Road, Chester, New York | 10918 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (845) 469-2042
not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered |
common stock, $0.01 par value | REPR | NASDAQ Capital Market |
ITEM 8.01 OTHER EVENTS.
Repro Med Systems, Inc. (the “Company”) is filing this Current Report on Form 8-K to report that effective October 24, 2019, the Company will begin using a new dba name, “KORU Medical Systems”, in place of “RMS Medical Products”. Reflecting this change, the Company’s common stock will commence trading under the new ticker symbol “KRMD” on the NASDAQ Capital Market effective October 24, 2019. On October 24, 2019 the Company’s email address will change to the domain@korumedical.com, and its home page will become www.korumedical.com.
On October 23, 2019, the Company issued a press release announcing the events set forth in this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press release dated October 23, 2019 |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| REPRO MED SYSTEMS, INC. | |
|
|
|
Date: October 23, 2019 | By: | /s/ Karen Fisher |
| Karen Fisher | |
- 3 -
Exhibit 99.1
FOR IMMEDIATE RELEASE
RMS MEDICAL PRODUCTS ANNOUNCES REBRANDING TO KORU MEDICAL SYSTEMS
NEW TICKER SYMBOL “KRMD”
CHESTER, NY – October 23, 2019 - Repro Med Systems, Inc. (NASDAQ: REPR) (“the Company”) today announced a new dba name, KORU Medical Systems, which the Company will begin using in place of RMS Medical Products on October 24, 2019. Reflecting this change, the Company’s common stock will commence trading under the new ticker symbol “KRMD” on the NASDAQ effective October 24, 2019.
The Company announced the rebranding on the eve of this year’s Immunoglobulin National Society Conference (IgNS 2019) in Las Vegas, Nevada, a unique, multi-disciplinary gathering of nurses, pharmacists, physicians, and Ig industry leaders. The Company’s management team and board of directors will be attending IgNS 2019.
“Our decision to rebrand the Company reflects the great strides we have made in evolving our corporate culture, mission, and philosophy to a more patient-centric focus,” said Don Pettigrew, President and CEO.
“The rebranding is inspired by the koru, a widely recognized symbol of a spiral-shaped, unfurling fern that represents new life and new beginnings,” said Mr. Pettigrew. “KORU Medical Systems’ focus on providing patients’ new beginnings with our at-home infusion systems is at the heart of our brand.”
On October 24, 2019 the Company’s email address will change to the domain @korumedical.com and its home page will become www.korumedical.com.
The Committee on Uniform Securities Identification Procedures (CUSIP) number assigned to the Company’s common stock will remain the same. The dba name change will not affect the rights of the Company’s stockholders. The Company’s corporate name, Repro Med Systems, Inc., will not change as a result of the dba name change at this time.
About the Company
The Company develops, manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.
Forward-Looking Statements
The statements contained herein include prospects, statements of future expectations and other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties, identified by words such as “will.” Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Factors that may cause actual results to differ materially from current expectations and other risks are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, which filings are available from the SEC and the Company’s website. The Company undertakes no obligation to update any forward-looking statements.
Contacts:
| The Equity Group Inc. | |
| Devin Sullivan | Kalle Ahl, CFA |
| Senior Vice President | Vice President |
| 212-836-9608 | 212-836-9614 |
| mailto: dsullivan@equityny.com | kahl@equityny.com |